| Molecular formula | C52H74N16O15S2 |
|---|
| Molecular weight | 1227.4 g/mol |
|---|
| Registered trials | 133 |
|---|
| PubChem CID | 72081 |
|---|
What terlipressin is
Terlipressin is a peptide compound (PubChem CID 72081) with a registered label on DailyMed, indicating it has an approved regulatory pathway on file. The label content detailing its specific mechanism, approved indications, and pharmacologic class was not available in the data provided, so those specifics are omitted here.
What the evidence shows
Terlipressin has been studied across 133 registered clinical trials. Among the available examples, one trial compared terlipressin with albumin against midodrine with albumin and albumin alone for preventing circulatory dysfunction after paracentesis in cirrhosis, and it is listed as completed. Another trial, examining hemoperfusion or plasma exchange against standard therapy in patients with acute on chronic liver failure, is also part of the broader research record. A third compared intramyometrial terlipressin to carbitocin for blood loss during myomectomy procedures and has reached completed status.
Reported side effects
No adverse event report data was available in the data provided for this compound, so this section is omitted.
FAQ
Terlipressin appears in clinical trials related to liver disease complications, including circulatory dysfunction in cirrhosis, and in surgical contexts such as blood loss management during myomectomy. It has been part of a broad research record of 133 registered trials. Specific approved indications were not detailed in the available label data.
Terlipressin has a registered label on file, which generally indicates an approved regulatory status. The detailed indications and mechanism text from that label were not available in this dataset, so specific approved uses cannot be listed here.
Terlipressin is a peptide compound with the molecular formula C52H74N16O15S2 and a molecular weight of approximately 1227.4. It is catalogued in PubChem under CID 72081.
No adverse event report data was available for terlipressin in the dataset used for this monograph. As a result, no side effect summary can be provided here.
Terlipressin has 133 registered clinical trials. Examples include studies on preventing circulatory dysfunction after paracentesis in cirrhosis and reducing blood loss during myomectomy procedures.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem CID 72081 ClinicalTrials.gov DailyMed
Updated 2026-11-07